Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
(Burns McClellan) Kite Pharma Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor T cell therapy.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news
More News: Burns | Cancer | Cancer & Oncology | Health | International Medicine & Public Health | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals